Document is current
Any future updates will be listed below
-
Authors
Michels, Monique https://orcid.org/0000-0001-8440-1976
Jesus, Gabriel Fernandes Alves
Voytena, Ana Paula Lorenzen https://orcid.org/0000-0002-4411-5526
Rossetto, Marina https://orcid.org/0000-0001-9410-3083
Ramlov, Fernanda https://orcid.org/0000-0001-7925-3980
Córneo, Emily https://orcid.org/0000-0003-4250-6635
Feuser, Paulo https://orcid.org/0000-0003-2372-8945
Gelain, Daniel https://orcid.org/0000-0001-5254-0509
Dal-Pizzol, Felipe https://orcid.org/0000-0003-3003-8977
-
Funding
Funding for this research was provided by:
UNESC
GABBIA
- License Information
-
More Information
Article History
Received: 4 March 2021
Accepted: 11 October 2021
First Online: 14 December 2021
Declarations
:
: Gabbia Biotechnology is developing paraprobiotics for the commercial purposes. Gabriel Jesus, Marina Rosseto, and Ana Paula Voytena are members of Gabbia Biotechnology. The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
: We confirm that the manuscript has been read and approved by all named authors and that there are no other persons who satisfied the criteria for authorship, but are not listed. We further confirm that the order of authors listed in the manuscript has been approved by all of us.
: Data will be made available on reasonable request.
